山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

SUMMARY

- For the six months ended 30 June 2026 (the "**Period**"), the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited (the "**Company**") and its subsidiaries (the "**Group**") was approximately RMB6,848,991,000 (same period in 2025: approximately RMB6,644,048,000), representing an increase of approximately 3.1% as compared with the same period last year, the unaudited net profit attributable to the owners of the Company was approximately RMB774,118,000 (same period in 2025: approximately RMB1,008,317,000), representing a decrease of approximately 23.2% as compared with the same period last year.

- Net profit attributable to the owners of the Company (excluding extraordinary items and the impact of exchange gains or losses) was approximately RMB890,438,000 (same period in 2025: approximately RMB1,008,438,000), representing a decrease of approximately 11.7% as compared to comparable figure over the same period last year. *(Notes)*

Note 1: During the Period, the extraordinary items comprised net expenses attributable to owners of the Company for equity incentives of approximately RMB19,981,000 and an one-off expense of approximately RMB4,960,000 (same period in 2025: a gain of approximately RMB72,933,000 arising from the dilution of the Company's equity interest in Shandong Weigao Blood Purification Products Co., Ltd. ("Weigao Blood Purification") to 23.90% and an one-off expense of approximately RMB31,711,000).

Note 2: During the Period, net exchange loss was approximately RMB91,379,000 (same period in 2025: approximately RMB41,343,000).

The board of directors (the "**Board**") proposed the distribution of an interim dividend for the six months ended 30 June 2026 of RMB0.0854 per share (same period in 2025: RMB0.0969 per share). The proposal is subject to the approval of shareholders of the Company (the "**Shareholders**") at the forthcoming extraordinary general meeting.

* *For identification purpose only*

UNAUDITED CONDENSED CONSOLIDATED INTERIM RESULTS

The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2026, together with the unaudited comparative figures for the same period* in 2025 as follows:

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

		Unaudited For the six months ended 30 June	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
Revenue	*3*	**6,848,991**	6,644,048
Cost of sales		**(3,678,332)**	(3,340,540)
Gross profit		**3,170,659**	3,303,508
Other income, gains and losses		**(19,110)**	117,158
Impairment losses under expected credit loss model		**(25,421)**	(12,595)
Selling expenses		**(1,070,905)**	(1,139,675)
Administration expenses		**(642,709)**	(650,181)
Research and development expenses		**(302,220)**	(325,312)
Finance costs	*4*	**(117,055)**	(116,773)
Share of results of associates		**49,802**	53,233
Share of results of joint ventures		**(10,541)**	(3,459)
Profit before taxation	*5*	**1,032,500**	1,225,904
Income tax expense	*6*	**(212,635)**	(168,919)
Profit for the Period		**819,865**	1,056,985

* The comparative figures for the prior period have been represented to reclassify certain items, mainly staff costs within selling, administrative expenses and research and development expenses by considering the functionality of those staffs, together with expenses of relevant activities of those staffs for each function, to align with current period's presentation. This reclassification has been made to ensure that the consolidated financial statements provide relevant, comparable, and understandable information to stakeholders. The reclassification does not affect the Group's financial performance or total expenses for the period presented.

		Unaudited For the six months ended 30 June	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
Other comprehensive income			
Exchange difference on translation of foreign operations		**(124,456)**	(66,421)
Total comprehensive income for the Period		**695,409**	990,564
Profit for the Period attributable to:			
Owners of the Company		**774,118**	1,008,317
Non-controlling interests		**45,747**	48,668
		819,865	1,056,985
Total comprehensive income attributable to:			
Owners of the Company		**659,777**	944,512
Non-controlling interests		**35,632**	46,052
		695,409	990,564
		RMB	*RMB*
Earnings per share (basic)	*7*	**0.17**	0.22
Earnings per share (diluted)	*8*	**0.17**	0.22

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Non-current assets			
Property, plant and equipment	*9*	**6,768,606**	6,801,940
Right-of-use assets		**660,704**	660,562
Investment properties		**125,266**	155,165
Goodwill		**3,656,232**	3,701,195
Deposits paid for acquiring property, plant and equipment		**83,491**	66,493
Intangible assets		**934,642**	1,044,965
Interests in associates		**1,791,989**	1,776,774
Interests in joint ventures		**322,529**	320,892
Financial assets at fair value through profit or loss		**64,659**	55,657
Deferred tax assets		**264,287**	259,656
Finance lease receivables		**2,335**	4,946
Loan receivables		**467,661**	312,365
Prepayments	*11*	**40,416**	44,907
Time deposits		**357,000**	180,000
		15,539,817	15,385,517
Current assets			
Inventories	*10*	**2,544,298**	2,515,073
Loan receivables		**264,137**	445,258
Trade and other receivables	*11*	**8,265,715**	7,826,887
Financial assets at fair value through profit or loss		**708,092**	388,822
Debt instruments at fair value through other comprehensive income		**423,665**	494,228
Finance lease receivables		**29,124**	9,185
Pledged/restricted bank deposits	*12*	**425,667**	413,622
Bank balances and cash	*13*	**7,362,697**	8,569,516
		20,023,395	20,662,591

	Notes	As at 30 June 2026 RMB'000 (Unaudited)	As at 31 December 2025 RMB'000 (Audited)
Current liabilities			
Trade and other payables	*14*	**4,675,151**	4,489,821
Contract liabilities		**327,352**	319,710
Borrowings		**1,244,434**	432,612
Taxation payable		**116,289**	136,567
Deferred income		**9,426**	13,502
Lease liabilities		**66,324**	65,813
Provisions		**10,542**	6,570
Financial liabilities at fair value through profit or loss		**31,069**	7,787
		6,480,587	5,472,382
Net current assets		**13,542,808**	15,190,209
Total assets less current liabilities		**29,082,625**	30,575,726
Capital and reserves			
Share capital		**457,063**	457,063
Reserves		**23,935,893**	23,651,114
Equity attributable to owners of the Company		**24,392,956**	24,108,177
Non-controlling interests		**1,776,595**	1,711,452
Total equity	*15*	**26,169,551**	25,819,629
Non-current liabilities			
Borrowings		**2,549,106**	3,357,900
Bonds payable		**–**	998,627
Financial liabilities at fair value through profit or loss		**–**	5,156
Deferred income		**54,055**	48,573
Deferred tax liabilities		**67,885**	66,066
Contract liabilities		**6,996**	9,926
Lease liabilities		**214,334**	248,489
Provisions		**20,698**	21,360
		2,913,074	4,756,097
		29,082,625	30,575,726

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW

	Unaudited For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Net cash inflow from operating activities	**1,077,691**	881,573
Net cash outflow from investing activities	**(658,145)**	(1,556,046)
Net cash before financing activities	**419,546**	(674,473)
Net cash (outflow) inflow from financing activities	**(1,328,475)**	833,293
Net increase in cash and cash equivalents	**(908,929)**	158,820
Cash and cash equivalents as at the beginning of the Period	**6,305,843**	4,942,882
Effect of foreign exchange rate changes	**(73,882)**	(3,696)
Cash and cash equivalents as at the end of the Period	**5,323,032**	5,098,006

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Unaudited For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Balance as at 1 January	**24,108,177**	23,751,643
Net profit for the Period	**774,118**	1,008,317
Dividends recognised as distribution	**(267,011)**	(555,879)
Share-based payments	**–**	10,805
Repurchase of shares of subsidiaries under a share incentive scheme	**–**	(3,903)
Repurchase of shares of the Company	**(107,987)**	(41,339)
Acquired interest in subsidiary from non-controlling shareholder	**–**	(1,296)
Exchange differences arising on translation of foreign operations	**(114,341)**	(63,805)
Balance as at 30 June	**24,392,956**	24,104,543

NOTES:

1. Overview

The Company was established and registered as a joint stock company with limited liability in the People's Republic of China (the "**PRC**") under the Company Law of the PRC on 28 December 2000 and its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Its immediate holding company is Weigao Holding Company Limited ("**Weigao Holding**"), and its ultimate holding company is Weihai Weigao International Medical Investment Holding Company Limited ("**Weihai Weigao International**"). Both Weigao Holding and Weihai Weigao International are registered in the PRC with limited liability. Its ultimate controlling party is Chen Xue Li. The address of the registered office and principal place of business of the Company is No. 1, Weigao Road, Weihai Torch Hi-Tech Science Park, Weihai, Shandong Province, PRC.

The Group is principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products and blood management products, and operate financing business.

The unaudited condensed consolidated financial statements are presented in Renminbi ("**RMB**"), which is the functional currency of the Company.

2. Basis of preparation and principal accounting policies

The condensed consolidated financial statements have been prepared in accordance with the "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants as well as the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The condensed consolidated financial statements have been prepared on the historical cost basis, except for certain financial instruments, which are measured at fair value, as appropriate.

Application of amendments to HKFRS Accounting Standards

In the current interim period, the Group has applied the following amendment to HKFRS Accounting Standards issued by the HKICPA, for the first time, which is mandatorily effective for the Group's annual period beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendment to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11

The application of the amendment to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. Revenue and segment information

For management purposes, the Group is currently organised into six operating divisions – medical device products, orthopaedic products, interventional products, pharma packaging products, blood management products and others, among which interventional products were produced by Argon. These divisions are the basis of the internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (Managing Director) in order to allocate resources to segments and to assess their performance.

Principal activities of the Group's operating and reportable segments are as follows:

Medical device business	–	production and sale of clinical care, anesthesia and surgical-related products, medical testing device
Orthopaedic business	–	production and sale of orthopaedic implants and consumables, orthopaedic intelligent equipment and consumables, functional repair and tissue regeneration
Interventional business	–	production and sale of tumour intervention and vascular intervention
Pharma packaging business	–	production and sale of prefilled syringes, prefilled flush syringes and automatic dosing device products
Blood management business	–	production and sale of blood collection, storage, separation and sterilization of consumable and equipment
Others	–	finance lease and factoring business

The segment information and results of those businesses are as follows:

For the six months ended 30 June 2026 (Unaudited)

	Medical device *RMB'000*	Orthopaedic *RMB'000*	Interventional *RMB'000*	Pharma packaging *RMB'000*	Blood management *RMB'000*	Others *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
Revenue								
External sales	3,478,027	698,234	963,417	1,253,572	454,392	–	–	6,847,642
Inter-segment sales	41,726	–	–	–	–	–	(41,726)	–
Total	3,519,753	698,234	963,417	1,253,572	454,392	–	(41,726)	6,847,642
Segment profit	466,620	163,350	(67,715)	479,136	53,105	16,416	–	1,110,912
Depreciation of investment properties								(2,818)
Unallocated other income, gains and losses								309
Rental income of investment properties								4,395
Interest income from bank deposits								64,748
Exchange rate gains or losses								(113,637)
Gain from changes in fair value of financial instruments at fair value through profit or loss								(29,278)
Share of results of associates								49,802
Share of results of joint ventures								(10,541)
Share-based payment expenses								(35,557)
Expense for early redemption of bonds								(5,835)
Profit before taxation								1,032,500

For the six months ended 30 June 2025 (Unaudited)

	Medical device *RMB'000*	Orthopaedic *RMB'000*	Interventional *RMB'000*	Pharma packaging *RMB'000*	Blood management *RMB'000*	Others *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
Revenue								
External sales	3,300,160	732,864	990,265	1,166,495	454,264	–	–	6,644,048
Inter-segment sales	52,041	–	–	–	–	–	(52,041)	–
Total	3,352,201	732,864	990,265	1,166,495	454,264	–	(52,041)	6,644,048
Segment profit	515,121	160,726	(60,000)	451,388	31,248	35,087	–	1,133,570
Depreciation of investment properties								(2,603)
Unallocated other income, gains and losses								(4,459)
Rental income of investment properties								5,830
Interest income from bank deposits								77,356
Gain from changes in fair value of financial instruments at fair value through profit or loss								(712)
Exchange rate gains or losses								(58,231)
Share of results of associates								53,233
Share of results of joint ventures								(3,459)
Share-based payment expenses								(13,015)
One-off expense related to value-added tax subsidy refunds								(34,539)
Gain on deemed disposal of investment in an associate								72,933
Profit before taxation								1,225,904

The accounting policies of the operating segments are the same as the Group's accounting policies. Segment profit represents the profit earned by each segment without allocation of depreciation and rental income of investment properties, unallocated other income, gains and losses of the corporate function, interest income from bank deposits, (loss)/gain on changes in fair value of financial instruments at FVTPL, share of results of associates/joint ventures, gain on deemed disposal of investment in an associate, gain on disposal of property, plant and equipment, expenses for early redemption of bonds and loss related to VAT subsidy refunds. This is the measure reported to the Managing Director for the purposes of resource allocation and performance assessment.

Inter-segment sales are charged at prevailing market rates.

4. Finance costs

Finance costs for the six months ended 30 June 2026 were approximately RMB117,055,000 (same period in 2025: approximately RMB116,773,000), which were mainly interest expenses on bank and other borrowings.

5. Profit before taxation

	Unaudited For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Profit before taxation has been arrived at after charging (crediting) the followings:		
Allowances for credit losses	**25,421**	12,595
Impairment losses on inventories	**10,464**	28,949
Amortization of intangible assets	**134,087**	145,118
Depreciation of property, plant and equipment	**346,128**	314,930
Depreciation of investment properties	**2,818**	2,603
Depreciation of right-of-use assets	**33,039**	23,439
Cost of inventories recognized as expenses	**3,678,332**	3,340,540
Staff costs, including directors' and supervisors' remuneration		
Retirement benefits scheme contribution	**108,656**	97,347
Salaries and other allowances	**1,340,464**	1,272,883
Share-based payment expenses	**35,557**	13,022
Total staff costs	**1,484,677**	1,383,252
Loss on disposal of property, plant and equipment	**3,178**	1,292

6. Income tax expense

Under the Law of the People's Republic of China on Enterprise Income Tax ("**EIT Law**") and Implementation Regulations of EIT Law, the tax rate of PRC subsidiaries is 25%.

In accordance with the Notice of the Ministry of Finance and the State Administration of Taxation Regarding Certain Preferential Treatment Policies on Enterprise Income Tax, new and high technology enterprises are subject to income tax at a tax rate of 15%.

The Company, Weihai Jierui Medical Products Company Limited (威海潔瑞醫用製品有限公司) ("**Jierui**"), Shandong Weigao Orthopaedic Device Company Limited ("**Weigao Orthopaedic**"), Weigao Medical Material Co., Ltd. (威海威高醫用材料有限公司), Weihai Weigao Jiesheng Medical Devices Co., Ltd. (威海威高潔盛醫療器械有限公司), Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. (山東威高普瑞醫藥包裝有限公司) and Shandong Weigao New Life Medical Device Co., Ltd. ("**Weigao New Life**") were recognized as Shandong Province New and High Technology Enterprises (山東省高新技術企業), Changzhou Jianli Bangde Medical Devices Co., Ltd. was recognized as Jiangsu Province New and High Technology Enterprises (江蘇省高新技術企業), Zhejiang Quantum Medical Devices Co., Ltd. ("**Zhejiang Quantum**") was recognized as Zhejiang Province New and High Technology Enterprises (浙江省高新技術企業), Weigao Fenwei Health Technology Development (Shanghai) Co., Ltd. was recognized as Shanghai New and High Technology Enterprises (上海市高新技術企業), and Zhuhai Wellcare Biotechnology Co., Ltd. (珠海維爾康生物科技有限公司) was recognized as Guangdong Province New and High Technology Enterprises (東省省高新技術企業). Therefore, they are subject to income tax at a rate of 15%.

Jierui and Shandong Weiteng Medical Products Co., Ltd. (山東威藤醫用製品有限公司) ("**Weiteng**") were recognised as a "Social Welfare Entity". Pursuant to Cai Shui [2016] No. 52 issued by the Ministry of Finance and the State Administration of Taxation, an amount equivalent to the total salaries paid to staff with physical disability is further deducted from the assessable profit of Jierui and Weiteng. The tax charge provided for the period ended 30 June 2026 was made after taking these tax incentives into account.

Taxation for other PRC subsidiaries is computed at a tax rate of 25% (2025: 25%).

In the USA, the Group is subject to the Federal corporate income tax at a tax rate of 21% plus tax rate of state governments.

The Group is operating in certain jurisdictions where the Global Anti-base Erosion Rules ("**Pillar Two Rules**") are effective or enacted but not effective. However, based on management's best estimate, the management of the Group considered the Group is not liable to top-up tax under the Pillar Two Rules.

7. Dividends

The Board recommends the distribution of an interim dividend of RMB0.0854 per share for the six months ended 30 June 2026 (same period in 2025: RMB0.0969 per share).

8. Earnings per share

For the six months ended 30 June 2026, basic earnings per share was calculated based on the net profits attributable to shareholders of approximately RMB774,118,000 (same period in 2025: approximately RMB1,008,317,000) and the weighted average total number of shares of 4,523,761,612 shares (same period in 2025: 4,543,114,720 shares).

For the six months ended 30 June 2026, diluted earnings per share was RMB0.17.

9. Property, plant and equipment

	Construction in progress	Freehold land	Buildings	Plant and machinery	Motor vehicles	Furniture, fixtures equipment and tools	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
COST							
As at 31 December 2024	839,468	8,889	4,024,345	4,192,170	83,603	1,339,090	10,487,565
Additions	632,856	–	39,500	248,425	2,428	45,920	969,129
Acquisition of a subsidiary	–	–	–	–	–	6,200	6,200
Transfer	(763,004)	–	250,260	473,125	3,428	36,191	–
Transfer between property, plant and equipment	–	–	–	161,054	3,935	(164,989)	–
Transfer from investment properties	–	–	26,407	–	–	–	26,407
Transfer to investment properties	–	–	(79,254)	–	–	–	(79,254)
Disposals	–	–	(1,514)	(157,566)	(3,984)	(59,686)	(222,750)
Adjustment on exchange rate	(1,034)	(322)	(2,771)	(9,098)	(60)	(5,911)	(19,196)
As at 31 December 2025	708,286	8,567	4,256,973	4,908,110	89,350	1,196,815	11,168,101
Additions	189,734	–	–	61,838	1,634	45,799	299,005
Acquisition of a subsidiary	–	–	–	1,537	832	1,546	3,915
Transfer	(159,416)	–	–	124,945	3,622	30,849	–
Transfer from investment properties	–	–	59,701	–	–	–	59,701
Disposals	–	–	–	(25,876)	(3,328)	(19,839)	(49,043)
Adjustment on exchange rate	–	(266)	(3,079)	(7,547)	(25)	(5,065)	(15,982)
As at 30 June 2026 (Unaudited)	738,604	8,301	4,313,595	5,063,007	92,085	1,250,105	11,465,697

	Construction in progress *RMB'000*	Freehold land *RMB'000*	Buildings *RMB'000*	Plant and machinery *RMB'000*	Motor vehicles *RMB'000*	Furniture, fixtures equipment and tools *RMB'000*	Total *RMB'000*
DEPRECIATION							
As at 31 December 2024	12,628	–	1,057,558	1,955,340	50,261	878,432	3,954,219
Depreciation provided for the year	–	–	142,530	392,643	7,188	71,658	614,019
Transfer between property, plant and equipment	–	–	–	89,429	3,389	(92,818)	–
Transfer from investment properties	–	–	7,756	–	–	–	7,756
Transfer to investment properties	–	–	(21,922)	–	–	–	(21,922)
Eliminated on disposals	–	–	(254)	(123,795)	(3,797)	(54,020)	(181,866)
Adjustment on exchange rate	–	–	(846)	(3,239)	(76)	(1,884)	(6,045)
As at 31 December 2025	12,628	–	1,184,822	2,310,378	56,965	801,368	4,366,161
Depreciation provided for the period	–	–	79,953	188,154	4,554	73,467	346,128
Transfer from investment properties	–	–	29,802	–	–	–	29,802
Eliminated on disposals	–	–	–	(21,466)	(779)	(15,746)	(37,991)
Adjustment on exchange rate	–	–	(840)	(2,806)	274	(3,637)	(7,009)
As at 30 June 2026 (Unaudited)	12,628	–	1,293,737	2,474,260	61,014	855,452	4,697,091
CARRYING VALUES							
As at 30 June 2026 (Unaudited)	725,976	8,301	3,019,858	2,588,747	31,071	394,653	6,768,606
As at 31 December 2025 (Audited)	695,658	8,567	3,072,151	2,597,732	32,385	395,447	6,801,940

10. Inventories

	30 June 2026 (Unaudited) *RMB'000*	31 December 2025 (Audited) *RMB'000*
Raw materials	**729,536**	649,785
Finished goods	**1,814,762**	1,865,288
	2,544,298	2,515,073

11. Trade and other receivables

	30 June 2026 (Unaudited) *RMB'000*	31 December 2025 (Audited) *RMB'000*
0 to 90 days	**2,682,612**	2,409,417
91 to 180 days	**1,587,497**	1,196,331
181 to 365 days	**1,477,790**	1,804,730
Over 365 days	**944,924**	739,946
Trade receivables	**6,692,823**	6,150,424
Receivables from factoring business	**171,619**	199,416
Other receivables	**693,992**	678,282
Prepayments	**747,697**	843,672
	8,306,131	7,871,794
Analysed for reporting purposes as:		
Current assets	**8,265,715**	7,826,887
Non-current assets	**40,416**	44,907
	8,306,131	7,871,794

12. Pledged/restricted bank deposits

The amounts represented deposits pledged to banks to secure trade facilities granted to the Group and the issuance of letter of guarantee. The amounts had been pledged to secure against the short-term bank loans and bank credit facilities and are therefore classified as current assets. The bank deposits carry interest rates ranging from 0.05% to 1.2% (same period in 2025: 0.05% to 1.1%) per annum.

13. Bank balances and cash

Cash and cash equivalents

Cash and cash equivalents include demand deposits and short-term deposits for the purpose of meeting the Group's short term cash commitments, the interest rate of which ranges from 0.05% to 4.0% (same period in 2025: 0.05% to 4.7%) per annum.

Time deposits

The Group's time deposits were issued by banks with original maturity over three months, the interest rate of which ranges from 1.0% to 3.75% (same period in 2025: 0.8% to 4.6%) per annum.

14. Trade and other payables

	30 June 2026 (Unaudited) *RMB'000*	31 December 2025 (Audited) *RMB'000*
0 to 90 days	**982,449**	839,518
91 to 180 days	**218,181**	180,612
181 to 365 days	**84,502**	67,805
Over 365 days	**115,423**	131,412
Trade payables	**1,400,555**	1,219,347
Bills payable	**810,131**	809,406
Other tax payables	**81,361**	97,276
Construction cost and retention payables	**80,750**	41,050
Selling expense payables	**818,205**	662,796
Other payables	**1,109,813**	1,442,841
Dividend payable	**251,005**	–
Consideration payable for the acquisition of Weigao New Life	**103,000**	103,000
Obligation arising on acquisition of Zhejiang Quantum	**20,331**	20,331
Repurchase obligation under share-based payments	**72,083**	72,083
Payables for cash-settled share-based payments	**–**	21,691
	4,675,151	4,489,821

15. Movement in reserves

	Share capital	Share premium reserve	Treasury shares	Statutory surplus reserve	Translation reserve	Share-based payments reserve	Other reserves	Retained earnings	Total	Non–controlling interests	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000* *Notes*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
As at 1 January 2025 (Audited)	457,063	2,743,144	–	263,686	313,040	241,136	(118,844)	19,852,418	23,751,643	1,589,923	25,341,566
Profit for the year	–	–	–	–	–	–	–	1,612,210	1,612,210	98,493	1,710,703
Other comprehensive income for the year	–	–	–	–	(120,973)	–	–	–	(120,973)	(8,060)	(129,033)
Total comprehensive income for the year	–	–	–	–	(120,973)	–	–	1,612,210	1,491,237	90,433	1,581,670
Reduced upon vested of incentive shares	–	–	–	–	–	–	34,583	–	34,583	–	34,583
Recognition of equity-settled share-based payments	–	–	–	–	–	–	–	–	–	73,969	73,969
Repurchase of shares of a subsidiary	–	–	–	–	–	–	(18,077)	–	(18,077)	(16,573)	(34,650)
Acquired interests by non-controlling interests upon vest of incentive shares of a subsidiary	–	–	–	–	–	–	(2,442)	–	(2,442)	14,942	12,500
Dividends recognised as distribution	–	–	–	–	–	–	–	(990,513)	(990,513)	(41,704)	(1,032,217)
Repurchase of shares	–	–	(159,479)	–	–	–	–	–	(159,479)	–	(159,479)
Withdraw the rights to purchase non-controlling interests of a subsidiary	–	–	–	–	–	–	1,225	–	1,225	462	1,687
As at 31 December 2025	457,063	2,743,144	(159,479)	263,686	192,067	241,136	(103,555)	20,474,115	24,108,177	1,711,452	25,819,629
Profit for the period	–	–	–	–	–	–	–	774,118	774,118	45,747	819,865
Other comprehensive income for the period	–	–	–	–	(114,341)	–	–	–	(114,341)	(10,115)	(124,456)
Total comprehensive income for the period	–	–	–	–	(114,341)	–	–	774,118	659,777	35,632	695,409
Recognition of equity-settled share-based payments	–	–	–	–	–	–	–	–	–	35,557	35,557
Acquisition of a subsidiary	–	–	–	–	–	–	–	–	–	19,619	19,619
Repurchase of shares *(Note)*	–	–	(107,987)	–	–	–	–	–	(107,987)	–	(107,987)
Dividends recognised as distribution	–	–	–	–	–	–	–	(267,011)	(267,011)	(25,665)	(292,676)
As at 30 June 2026 (Unaudited)	457,063	2,743,144	(267,466)	263,686	77,726	241,136	(103,555)	20,981,222	24,392,956	1,776,595	26,169,551

Notes:

(a) Bases for appropriation to reserves

Appropriation to statutory surplus reserve and statutory public welfare fund has been calculated based on the net profits in the financial statement prepared under the generally accepted accounting principles in the PRC ("**PRC GAAP**").

(b) Statutory surplus reserve

The Articles of Association of the companies under the Group (other than overseas companies) requires that 10% of the profit after taxation for each year (prepared in accordance with the PRC GAAP) should be transferred to the statutory surplus reserve, until it has reached 50% of the registered capital. Pursuant to the Articles of Association of the companies under the Group, under normal circumstances, statutory surplus reserve can only be used to make up for the losses, converted into share capital by way of capitalisation, and for the expansion of the Company's production and operation scope. In the event of converting the statutory surplus reserve into share capital by way of capitalisation, the balance of such reserve shall not be less than 25% of the registered capital.

(c) Statutory public welfare fund

According to the Company Law of the PRC and the amended Articles of Association of the Company, from 1 January 2006 onwards, the companies under the Group ceased to transfer funds from statutory public welfare fund. The statutory public welfare fund as of 31 December 2005 was part of the share capital of the shareholders, which cannot be distributed other than for the purpose of liquidation. Pursuant to the board resolution of the Company, in accordance with the Company Law of the PRC, the Company transferred an amount of RMB17,147,000 from statutory public welfare fund to the statutory surplus reserve on 1 January 2006.

(d) Repurchase of shares of the Company

Pursuant to the resolutions of the shareholders passed at the annual general meeting of the Company (the "**AGM**") held 28 May 2024, the Company granted a general mandate to its directors to repurchase shares of the Company not exceeding 10% of the aggregate nominal value of H Shares in issue (excluding any treasury shares). For the six months ended 30 June 2026, 29,000,800 ordinary shares have been repurchased with par value of RMB0.1 each, with a total consideration of HKD121,640,000 (approximately RMB107,987,000).

According to the laws and regulations of the PRC, the distributable profit of the Company was determined at the lower of such amount computed based on the accounting principles and regulations of the PRC or the generally accepted accounting principles in Hong Kong. As of 30 June 2026, the retained earnings available for distribution to shareholders was approximately RMB9,492,530,000.

MANAGEMENT DISCUSSION AND ANALYSIS

Optimisation of product mix

During the Period, the gross profit margin of the Group amounted to 46.3%, representing a decrease of 3.4 percentage points from 49.7% in the same period last year, primarily due to the factors such as a decline in selling prices of the generic medical device, orthopaedic and flushing syringe products resulting from policy changes.

The existing major products of the Group are as follows:

- The medical device products include clinical care, anesthesia and surgical-related products, medical testing equipment

- The orthopaedic products include orthopaedic implants and consumables, orthopedic intelligent equipment and consumables, functional repair and tissue regeneration

- Interventional products include tumor intervention, vascular intervention, and interventional imaging

- The pharmaceutical packaging products include prefilled syringes, pre-filled flush syringes and automatic dosing device products

- The blood management products include blood collection, storage, separation, and sterilization of consumables and equipment

1. During the Period, medical device products recorded a turnover of approximately RMB3,363,722,000, representing an increase of 5.4% over corresponding period. Despite the growth in turnover, since the third quarter of 2025, operating profit declined by nearly 10% year-on-year due to decrease in the selling prices of certain core products resulting from the centralized procurement policy. Nevertheless, through adjustments to its product mix and substantial optimization of marketing expenses, among other measures, the Company achieved a significant sequential increase in operating profit, while maintaining an operating profit margin of above 10%.

2. During the Year, the orthopaedic products recorded a turnover of approximately RMB698,234,000, representing a decrease of 4.7% over corresponding period. Mainly affected by several factors such as intensified market competition and fluctuations in clinical surgical procedure volumes, both sales volume and revenue declined year on year. However, after excluding share-based compensation expenses, the segment's profit still achieved a marginal increase of 1.6%.

3. During the Year, the interventional products recorded a turnover of approximately RMB1,079,077,000, representing a decrease of 1.9% over corresponding period. The decrease in business performance of Argon, a subsidiary, was mainly attributable to the significant negative impact of exchange rate gains or losses. Company's new products, such as Cleaner Vac, achieved rapid growth in line with its plan, driving the growth recovery of this segment.

4. During the Year, the pharmaceutical packaging products recorded a turnover of approximately RMB1,253,565,000, representing an increase of 7.5% over last year. Among them, prefilled syringes maintained a double-digit year-on-year growth and gradually increased the proportion of overseas sales, while flushing syringes saw a significant decrease in selling prices due to the implementation of the latest volume-based procurement prices, which dragged down the overall revenue performance of the segment.

RESEARCH AND DEVELOPMENT

For the six months ended 30 June 2026, the Group had 150 new patents and 123 patents are under application in the PRC. New product registration certificates for 129 products were obtained. The research and development for 46 products were completed for which applications for product registration certificates are underway. For overseas market, 33 new patents are under application and the research and development for 155 products were completed for which application for product registration certificates are underway.

The strategy of placing strong emphasis on research and development has enhanced the Company's core competitiveness and laid a solid foundation to fully leverage on its customer resources and also provided the Group with continuous new profit growth drivers.

As at 30 June 2026, the Group had 987 product registration certificates and 1,247 patents, of which 312 were patents on invention, in the PRC. For overseas market, the Group had 1,314 product registration certificates and 270 patents.

In view of the need for the strategic adjustments to product mix, the Group continued to invest in the research and development in existing products series and several new medical devices, so as to further improve its product mix under sub-classification of medical devices product types. For the six months ended 30 June 2026, total research and development expenses amounted to approximately RMB302,220,000 (same period in 2025: approximately RMB325,312,000), representing 4.4% (same period in 2025: 4.9%) of the revenue of the Group.

PRODUCTION

During the Period, the Group continued to increase its investment in capacity expansion and production facilities based on market demand and long-term development plans. We focused on introducing advanced equipment such as high-performance automated equipment, AI visual inspection, and high-efficiency moulds. Through adding intelligent production lines for core products, we not only significantly improved production efficiency but also realized the optimization and upgrading of production processes with significant improvement in automation and intelligence levels, successfully achieving a transition to high-tech processing and manufacturing. In terms of cost control, manufacturing costs have significantly decreased. By improving the supply chain to reduce material costs, combined with labour savings and manufacturing cost control measures, we ensured the implementation of "cost reduction, efficiency improvement, and quality assurance initiatives". This has ultimately safeguarded the stability and enhancement of the Company's overall profitability, laying a solid foundation for expanding market share through enhanced production capacity and cost advantage, and further strengthening the core competitiveness of its products.

SALES AND MARKETING

The Group continues to implement the strategy in integrating its sales channels and adjusting its product mix. Domestically, we accelerate grassroots market layout, whilst focusing on high-potential markets for comprehensive development overseas. As at 30 June 2026, the Group had nearly 17,600 customers (comprising approximately 9,500 domestic customers and approximately 8,100 overseas customers).

Information about the Group's revenue from external customers is presented based on the location of the customers. Sales proportion for various products by geographical regions when compared with the same period last year is set out as follows:

Turnover by Geographical Locations

Regions	**Unaudited For the six months ended 30 June**				Over corresponding period
	2026		2025		
	RMB'000	***%***	*RMB'000*	*%*	%
The PRC					
– Eastern and Central	**2,758,687**	**40.3**	2,615,195	39.4	5.5
– Northern	**836,349**	**12.2**	886,491	13.3	(5.7)
– Southern	**634,353**	**9.3**	604,369	9.1	5.0
– Northeast	**398,254**	**5.8**	418,128	6.3	(4.8)
– Southwest	**388,170**	**5.7**	377,238	5.7	2.9
– Northwest	**109,460**	**1.6**	118,896	1.8	(7.9)
PRC sub-total	**5,125,273**	**74.9**	5,020,317	75.6	2.1
Overseas					
– The US	**699,562**	**10.2**	723,702	10.9	(3.3)
– Asia and others	**555,456**	**8.1**	487,345	7.3	14.0
– Europe, Middle East and Africa	**468,700**	**6.8**	412,684	6.2	13.6
Overseas sub-total	**1,723,718**	**25.1**	1,623,731	24.4	6.2
Total	**6,848,991**	**100.0**	6,644,048	100.0	3.1

Comparison of sales revenue of principal products with that in the same period last year is as follows:

Product category	Unaudited For the six months ended 30 June **2026** ***RMB'000***	 2025 *RMB'000*	Over corresponding period *%*
Medical device product	**3,363,722**	3,190,538	5.4
Orthopaedic product	**698,234**	732,864	(4.7)
Interventional product	**1,079,077**	1,099,887	(1.9)
Pharma packaging product	**1,253,565**	1,166,495	7.5
Blood management product	**454,393**	454,264	0
Total	**6,848,991**	6,644,048	3.1

HUMAN RESOURCES

As at 30 June 2026, the Group employed a total of 13,310 employees. The breakdown by departments when compared with last year is as follows:

Department	**As at 30 June 2026**	As at 31 December 2025
Production and operations	**7,846**	7,709
Sales and marketing	**3,283**	3,343
Research and development	**1,188**	1,264
Finance and administration	**653**	648
Management	**340**	343
Total	**13,310**	13,307

A total of 1,347 overseas employees reside in the US, Europe and Hong Kong. Other employees of the Group reside in Mainland China. During the Period, total cost of salaries, welfare and social benefits of the Group amounted to approximately RMB1,484,677,000 (same period in 2025: approximately RMB1,383,252,000).

Remuneration System

The Group's remuneration policy has been determined based on its performance, local consumption power and competition in human resources market. The remuneration policy so determined has become the basis of determining the salary level of employees recruited for different positions. The salary of each employee is determined according to the employee's performance, ability, employment conditions and the salary standards set by the Company. Remuneration of Directors is proposed by the Remuneration Committee with reference to the operating results of the Company, personal performance of the Directors and market competition. The remuneration of Directors is determined by the Board subject to approval by shareholders at the annual general meeting.

FINANCIAL REVIEW

For the six months ended 30 June 2026, the turnover reached approximately RMB6,848,991,000, representing an increase of approximately 3.1% over the same period last year. Net profit attributable to owners of the Company was approximately RMB774,118,000, representing a decrease of approximately 23.2% as compared to the same period last year. Net profit attributable to the owners of the Company (excluding extraordinary items and the impact of exchange gains or losses) was approximately RMB890,438,000, representing a decrease of approximately 11.7% as compared to comparable figure (same period in 2025: approximately RMB1,008,438,000) over the same period last year.

FINANCIAL SUMMARY

	Unaudited For the six months ended 30 June		Increase
	2026	2025	**(decrease)**
	RMB'000	*RMB'000*	*%*
Turnover	**6,848,991**	6,644,048	3.1%
Gross profit	**3,170,659**	3,303,508	(4.0%)
Net profit attributable to the owners of the Company	**774,118**	1,008,317	(23.2%)
Net profit attributable to the owners of the Company (excluding extraordinary items and the impact of exchange gains or losses)	**890,438**	1,008,438	(11.7%)

During the Period, the extraordinary items comprised net expenses attributable to owners of the Company for equity incentives of approximately RMB19,981,000 and an one-off expense of approximately RMB4,960,000 (same period in 2025: a gain of approximately RMB72,933,000 arising from the dilution of the Company's equity interest in Shandong Weigao Blood Purification Products Co., Ltd. ("**Weigao Blood Purification**") to 23.90% and an one-off expense of approximately RMB31,711,000).

During the Period, net exchange loss was approximately RMB91,379,000 (same period in 2025: approximately RMB41,343,000).

Liquidity and Financial Resources

The Group has maintained a sound financial position. As at 30 June 2026, the Group's cash and bank balance amounted to approximately RMB7,719,697,000. For the six months ended 30 June 2026, net cash flow from operating activities of the Group amounted to approximately RMB1,077,691,000, representing a sound cash flow position.

Total interest expenses of the Group for the six months ended 30 June 2026 were approximately RMB117,055,000 (same period in 2025: approximately RMB116,773,000).

Gearing Ratio

As at 30 June 2026, the gearing ratio of the Group was 16.7% (31 December 2025: 21.2%). The gearing ratio represents total debt as a percentage of total capital. Total debt is calculated as total borrowings and bonds payable. Total capital is calculated as the equity attributable to owners of the Company.

Foreign Exchange Risks

The Group's purchases and sales are mainly conducted in the PRC and the United States. Assets, liabilities and transactions in the PRC are denominated in RMB, while overseas assets and transactions are mainly denominated in US dollars. Foreign exchange risk mainly arises from unsettled borrowings denominated in foreign currencies. The Group has adopted foreign currency hedging instruments to achieve better foreign exchange risk management. The objective of the hedge is to minimise the volatility of the RMB expenditures expected to be incurred in the future to meet foreign currency liabilities. The Group's risk management policy is to partially hedge the forecasted cash flows in foreign currencies by considering the appropriate hedging instruments and costs of hedging. The Group uses foreign exchange structured derivative financial contracts to hedge its foreign currency risk. For the six months ended 30 June 2026, the Group had not encountered any material difficulty due to currency fluctuation nor had it affected its funds for operation purpose.

Due to the fluctuation in exchange rates, foreign exchange loss equivalent to RMB113,663,000 (same period in 2025: foreign exchange loss equivalent to RMB58,230,000) for the six months ended 30 June 2026 was recorded by the Company.

Material Investments in Subsidiaries/Future Material Investment Plans

1. During the Period, the Group continued to invest approximately RMB336,590,000 in the purchase of property, production facilities and plant construction for the purpose of enhancing the overall construction of the industrial zone for the Group's medical consumables.

2. The Group planned to invest RMB770,000,000 to acquire the 38.5% interest in the Songyuan Healthcare Industry Fund (松源健康醫療產業基金), which focuses on the investments in the medical and healthcare sector mainly covering medical devices, biopharmaceuticals, medical services and rehabilitation and elderly care, of which a total of RMB308,000,000 has been contributed.

3. During the Period, a new production line for pre-filled syringes and a production line for auto-injectors with a planned investment of approximately RMB200,000,000 is under construction and is expected to be successively put into operation in 2026 and 2027.

4. During the Period, construction was underway for the planned investment of approximately RMB400,000,000 for upgrading and reconfiguration of the single-use consumables and orthopaedic consumables production equipment to further expand production capacity and enhance the level of production automation.

5. During the Period, the Group acquired a partial equity interest in Suzhou Jiesbyer Medical Technology Co., Ltd. and inject additional capital for approximately RMB83,025,000. Upon completion of the transaction, the Group will hold its 55% equity interest, thereby acquiring its two established product lines including minimally invasive orthopaedic solution and active energy platform, as well as its production capabilities.

6. The Group plans to establish a partnership with a private equity fund for approximately RMB60,000,000, which is primarily used to invest in companies or projects in the healthcare sector that are in the growth or mature stages, of which a total of RMB2,000,000 has been contributed.

7. The Group plans to invest KRW15,890,000,000 (approximately RMB73,567,000) in a fund, accounting for approximately 30%. The fund will be principally engaged in investments in small and medium-sized enterprises and mid-tier enterprises in Korea and overseas in sectors focusing on open innovation and overseas business expansion involving Korean and overseas enterprises, universities and research institutions, of which a total of KRW4,568,000,000 (approximately RMB21,149,000) has been contributed.

8. In January 2023, Weigao Orthopaedic, a subsidiary of the Company acquired 100% equity interest in Shandong Weigao Newlife Medical Device Co., Ltd., a fellow subsidiary of the Company, which is principally engaged in the research and development, manufacture and sale of tissue repair product lines, at a consideration of RMB1,030,000,000. The transfer price is payable in instalments, with RMB103,000,000 is expected to be paid in the second half of the year.

Save for the above material investments and investment plans, the Group had no any future plans involving significant investments or capital assets acquisition as at 30 June 2026.

Capital Commitment

As at 30 June 2026, the capital commitment that the Group and the Company had contracted for but not provided in the financial statements amounted to approximately RMB916,917,000 (same period in 2025: approximately RMB1,030,768,000).

REVIEW & OUTLOOK

In the first half of 2026, domestic demand in the healthcare sector showed certain signs of recovery, with outpatient visits and number of surgical operations in public hospitals picking up compared with the same period last year. However, the pace of recovery remained retardant, and budgetary constraints and cautious procurement practices among healthcare institutions remained prominent. Volume-based procurement of medical consumables and equipment continued to be implemented and amid marginal downward pressure on prices for most products has eased, the impact on existing business remains significant. The Company's revenue increased slightly in the first half of the year, but gross profit margins came under pressure and experienced a decline with the overall net profit margin yet to stabilise.

From the external perspective, frequent geopolitical conflicts worldwide broke out during the first half of the year, with divergent monetary policies among major economies and significant two-way fluctuations in exchange rates emerged. During the reporting period, the Company incurred exchange losses of a considerable magnitude. Changes to trade tariffs and market access regulations in certain overseas regions have increased compliance and operational costs for foreign trade operations, while hampering the further growth of its overseas business. The Company will continue to stick to its globalisation strategy amidst this volatile environment. For the first half of the year, the growth rate of overseas revenue was slightly higher than that of the Chinese domestic market.

By segment, the generic medical device segment recorded a slight increase in revenue during the reporting period. However, since the third quarter of 2025, significant price reductions for products in several key regions have led to a marked decline in the gross profit margin for this segment. Nevertheless, through the ongoing optimisation of the product mix and efforts to reduce marketing expenses, the profit margin for this segment remained above 10% in the first half of the year, showing a significant improvement quarter-on-quarter.

Revenue from the orthopedic segment fell slightly compared with the same period last year. Affected by factors such as the re-tendering of certain orthopaedic products, hospitals adopted a cautious procurement approach. Coupled with intensified market competition and fluctuations in the number of clinical operations, this led to a slight year-on-year decline in the sales of orthopaedic products during the first half of the year. After adjusting for share-based payment expenses, segment profit recorded a modest increase of 1.6%. The Company will adhere to its differentiated competitive strategy, continue to refine its upstream and downstream industrial chain layout in the orthopaedic sector, and advance rapid growth in high-potential segments such as intelligent equipment and consumables, functional repair and tissue regeneration, and sports medicine, thereby enhancing its capacity to provide comprehensive solutions.

In the interventional segment, the mature product business of Argon, a subsidiary, remained robust. Revenue, denominated in RMB, declined slightly due to the impact of exchange rate fluctuations. The new thrombectomy device, Cleaner Vac, continued to maintain a high growth trajectory. However, the corresponding costs for commercialised promotion, market education and clinical research remained increasingly high, resulting in reporting a temporary loss for this subsidiary during the reporting period. The Company continues to strengthen Argon's internal governance framework, optimise organisational operational efficiency, accelerate its expansion into emerging markets outside Europe and the US, thereby consistently unleashing the strategic value of its platform.

In the pharmaceutical packaging business, prefilled syringes' market position continued to consolidate. Coupled with faster-than-expected overseas growth, revenue achieved high single-digit growth. However, revenue from prefilled flush syringes was affected by the implementation of volume-based procurement pricing, which dragged down the overall revenue performance of the segment. The auto-injector business faced a relatively intense market competition. The Company continues to optimise its production lines and expects to complete the upgrade and refurbishment of new production lines by 2027, which will significantly enhance operational efficiency on the manufacturing side and optimise production costs.

Amid a complex and ever-changing internal and external environment, the Company has remained committed to the overarching goal of high-quality development, proactively pushing forward adjustment to its business structure to mitigate the operating risks associated with reliance on a single sector or market. The asset swap transaction with Weigao Blood Purification was approved by the Mergers, Acquisitions and Reorganization Review Committee of the Shanghai Stock Exchange in August 2026, but remains subject to the registration approval by the China Securities Regulatory Commission before it can be implemented. Upon completion of this transaction, the listed company will expand into high-quality sectors such as blood purification and the upstream biopharmaceutical sector, thereby further broadening its business scope and strengthening the competitiveness of its comprehensive medical device platform.

The Company will continue to advance its two core strategic pillars of R&D innovation and globalisation. On the R&D front, it will accelerate its footprint in high-potential areas such as broad surgical segment, explore integrated “device-plus-consumable” solutions, and drive the commercialisation of innovative products. On the global expansion aspect, the Company’s joint venture in Indonesia is scheduled to commence local manufacturing in the second half year. Meanwhile, the Company is pursuing localised operations across more overseas markets, expanding its global footprints under a region-specific approach.

Looking forward into the second half of the year, uncertainty in the global geopolitical landscape is expected to persist. Raw material price volatility will likely continue to put pressure on production costs, while new rounds of centralized volume-based procurement for medical devices are set to roll out across several regions in China, sustaining the downward price trend. The Company will stay committed to its innovation-led transformation and internationalisation strategy, consolidate its existing businesses while aggressively expanding new growth scale, and transition itself from a leading domestic consumables manufacturer to an integrated international medical device company spanning both equipment and consumables.

PROPOSED INTERIM DIVIDEND

The Board recommended the distribution of an interim dividend of RMB0.0854 per share (corresponding period in 2025: RMB0.0969 per share) for the six months ended 30 June 2026. Such proposal is subject to the approval of the shareholders of the Company (the "**Shareholders**") at the forthcoming extraordinary general meeting of the Company to be held on Friday, 16 October 2026 ("**Extraordinary General Meeting**").

CLOSURE OF REGISTER OF MEMBERS

For Extraordinary General Meeting

In order to determine the shareholders who are entitled to attend and vote at the Extraordinary General Meeting (or any adjournment or postponement thereof), the register of members of the Company for H Shares will be closed from Monday, 12 October 2026 to Friday, 16 October 2026 (both days inclusive), during which period no transfer of H Shares will be effected. In order to qualify for attending and voting at the Extraordinary General Meeting (or any adjournment or postponement thereof), Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Friday, 9 October 2026.

Key dates for the Extraordinary General Meeting:–

Latest time to lodge in the transfer instrument accompanied by the share certificates	4:30 p.m., Friday, 9 October 2026
Closure of register of members of the Company	Monday, 12 October 2026 to Friday, 16 October 2026
Record date	Friday, 16 October 2026
Date of Extraordinary General Meeting	Friday, 16 October 2026

For Interim Dividend

In order to determine the entitlement to the interim dividend payment, the register of members of the Company for H Shares will be closed on Friday, 23 October 2026, during which period no transfer of H Shares will be effected. In order to qualify for entitlement of the interim dividend, holders of H Shares should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F., Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Thursday, 22 October 2026.

The interim dividend will be despatched at the risk of those entitled thereto to their respective registered addresses on or before Friday, 20 November 2026. The applicable exchange rate for converting RMB into Hong Kong dollar for the purpose of the interim dividend payment will be based on the average middle exchange rate of Renminbi as quoted by the People's Bank of China for the calendar week preceding 16 October 2026, the date on which the interim dividend to be declared.

Keys dates for the interim dividend:

Ex-dividend date	Wednesday, 21 October 2026
Latest time to lodge in the transfer instrument accompanied by the share certificates	4:30 p.m., Thursday, 22 October 2026
Closure of register of members of the Company	Friday, 23 October 2026
Record date	Friday, 23 October 2026
Payment date of interim dividend	Friday, 20 November 2026

INCENTIVE SHARE SCHEME

The Company adopted an inventive share scheme on 17 November 2014 ("**2014 Incentive Share Scheme**") which was expired on 16 November 2024. No share awards will be granted from the 2014 Incentive Share Scheme after its expiry.

Details of the movement of the share awards granted pursuant to the 2014 Incentive Share Scheme during the Year were as follows:

		Number of share awards							
Name of grantee	**Date of grant**	**Exercisable as at 1 January 2026**	**Vested during the Period**	**Exercised during the Period**	**Cancelled during the Period**	**Lapsed during the Period**	**Exercisable as at 30 June 2026**	**Subscription price upon grant (RMB)**	**Weighted average closing price of the shares immediately before the dates the awards were exercised or vested (HKD)**
Directors									
Mr. Long Jing	24/12/2021 (batch 2)	4,800,000	–	–	–	–	4,800,000	3.58	N/A
Mr. Cong Rinan	24/12/2021 (batch 2)	1,600,000	–	–	–	–	1,600,000	3.58	N/A
Mr. Wang Daomimg	24/12/2021 (batch 2)	300,000	–	–	–	–	300,000	3.58	N/A
Other Eligible Participants									
Employees	24/12/2021 (batch 2)	21,450,000	–	–	–	–	21,450,000	3.58	N/A

2025 H Share Incentive Scheme

The Company adopted the 2025 H Share Incentive Scheme by an ordinary resolution passed at the extraordinary general meeting of the Company on 17 October 2025. Summary of the principal terms of the 2025 H Share Incentive Scheme are as below:

Purpose

The purposes of the 2025 H Share Incentive Scheme are to: (i) attract and retain eligible participants whose contributions are important to the long-term growth and success of the Group, and to recognize and reward eligible participants for their past contributions to the Group; (ii) encourage eligible participants to further contribute to the Company and work towards enhancing the value of the Company and its Shares for the benefit of the Company and its shareholders as a whole; (iii) enhance the Company's long-term remuneration incentive strategy; and (iv) to align the interests of the eligible participants with those of the Company and the Shareholders to promote the long-term performance (whether in financial, business and operational aspects) of the Group.

Eligible Participants

Subject to the Scheme Rules, the Board may, from time to time, at its absolute discretion select any Eligible Participant (other than any Excluded Participant) for participation in the 2025 H Share Incentive Scheme as a Selected Participant, and grant Award Shares to any Selected Participant at such consideration and subject to such terms and conditions as the Board may in its absolute discretion determine. There are two types of awards that may be granted under the 2025 H Share Incentive Scheme: two-year award and one-year award.

Scheme Mandate Limit

Subject to the Scheme Rules, the total number of H Shares which may be issued (including transfer of treasury shares out of treasury) in respect of all options and awards to be granted under the 2025 H Share Incentive Scheme and any other share scheme(s) adopted by the Company must not exceed 4.5% of the total number of issued Shares (excluding treasury shares) as at the Adoption Date. As of the Latest Practicable Date, the Company did not have any other existing share scheme subject to the forgoing limit. For the avoidance of doubt, under the 2025 H Share Incentive Scheme, the Scheme Mandate Limit is applicable to the grant of Award Shares to be satisfied by both the transfer of treasury shares and/or existing H Shares.

Vesting Period

The vesting period for the Award Shares shall not be less than 12 months. The Directors are of the view that a vesting period of no less than 12 months would allow the Group to promote long-term commitment and stability among Eligible Participants, which aligns with the purpose of the 2025 H Share Incentive Scheme.

Performance Targets

The performance targets will be linked to the individual Employee Participant and/or the Group as a whole or to a subsidiary (if established), department, division, region, function or business unit, line of business, project or individual key performance indicators, which may include corporate sustainability parameter and discipline and responsibility. In addition, the performance targets of certain individual Employee Participants may be linked to sales performance (e.g. revenue) and financial performance (e.g. profits, cash flow). The Remuneration Committee can propose other performance targets to be stated in the Letter of Grant to the Board from time to time. The Remuneration Committee will conduct assessment from time to time by comparing the performance with the pre-set targets, past or current performance or comparison to internal targets or industry performance, to determine whether such targets and the extents to which have been met.

As at 30 June 2026, no share awards were granted under the 2025 H Share Incentive Scheme.

DISCLOSURE OF INTERESTS

Directors' and Chief Executives' Interests and Short Position

As at 30 June 2026, the interests and short positions of the Directors and the chief executives of the Company in the shares, underlying shares and debentures of the Company or of any associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "**SFO**")) of the Company, which will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of the SFO) or which will be required, as recorded in the register maintained by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as contained in Appendix C3 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") were as follows:

(i) Long positions in the shares and underlying shares of the Company:

Name of director	Nature of interest	Capacity	Number of H Shares held	% of H Shares in issue *(note 1)*	Number of Domestic Shares held	% of Domestic Shares in issue *(note 1)*	% of the total issued share capital of the Company *(note 1)*
Mr. Long Jing *(Note 2)*	Personal	Beneficial Owner	–	–	4,800,000	9.94	0.1050
Mr. Cong Rinan *(Note 3)*	Personal	Beneficial Owner	–	–	1,600,000	3.31	0.0350
Mr. Wang Daoming *(Note 4)*	Personal	Beneficial Owner	–	–	300,000	0.62	0.0066
Mr. Chen Lin	Personal	Beneficial Owner	196,000	0.0043	–	–	0.0043

Notes:

1. As at 30 June 2026, the number of total issued shares of the Company was 4,570,632,324, comprising 4,522,332,324 H Shares and 48,300,000 Domestic Shares.

2. The interest disclosed represents 4,800,000 unlisted incentive shares vested pursuant to the 2014 Incentive Share Scheme.

3. The interest disclosed represents 1,600,000 unlisted incentive shares vested pursuant to the 2014 Incentive Share Scheme.

4. The interests disclosed represents 300,000 unlisted incentive shares vested pursuant to the 2014 Incentive Share Scheme.

(ii) Long positions in the shares and underlying shares of the associated corporations of the Company

Name of director	Name of associated corporation	Nature of interest	Amount of equity interest held	% of interest in the associated corporation
Mr. Chen Lin	Weihai Weigao International Medical Investment Holding Co., Ltd. *(Note i)*	Beneficial owner	RMB1,100,800	6.90%
	Weigao Holding Company Limited *(Note i)*		RMB9,760,000	0.81%
Mr. Lu Junqiang	Shandong Weigao Orthopaedic Device Company Limited	Beneficial owner	400,000 A shares *(Note ii)*	0.10%

Notes:

(i) Weihai Weigao International Medical Investment Holding Co., Ltd. ("**Weihai Weigao International**") holds 89.93% equity interest in Weigao Holding Company Limited ("**Weigao Holding**"), which is the controlling shareholder of the Company holding 46.51% equity interest in the Company.

(ii) These underlying shares were incentive share options granted to Mr. Lu Junqiang and were vested pursuant to the share award scheme of Shandong Weigao Orthopaedic Device Company Limited, a subsidiary of the Company listed on the Shanghai Stock Exchange.

Save as disclosed above, as at 30 June 2026, none of the Directors and chief executive of the Company had any interests or short position in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of the SFO) which (a) were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the SFO (including the interests and short positions which the Director is taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) were required, pursuant to the Model Code to be notified to the Company and the Stock Exchange.

Substantial Shareholders

As at 30 June 2026, so far as the Directors are aware, the following persons (other than the Directors and the chief executive of the Company) or institutions have interests or short positions of 5% or more in the shares or underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO:

Name of shareholder	Nature of interest	Number of H Shares held *(Note 2)*	% of total issued share capital *(Note 1)*
Mr. Chen Xueli	Interest of controlled corporation	2,125,750,476 (L)	46.51
Weihai Weigao International	Interest of controlled corporation	2,125,750,476 (L)	46.51
Weigao Holding	Beneficial owner	2,008,750,476 (L)	43.95
	Interest of controlled corporation	117,000,000 (L)	2.56
Wego International Capital Holding Corporation Limited	Beneficial owner	117,000,000 (L)	2.56

Notes:

1. As at 30 June 2026, the number of total issued shares of the Company was 4,570,632,324, comprising 4,522,332,324 H Shares and 48,300,000 Domestic Shares.

2. Wego International Capital Holding Corporation Limited ("**Wego Capital**") is 100% owned by Weigao Holding. The Company is owned as to 46.51% by Weigao Holding, which is 89.83% owned by Weihai Weigao International. Weihai Weigao International is 50.80% owned by Mr. Chen Xueli. Accordingly, Mr. Chen Xueli and Weihai Weigao International are deemed to be interested in the shares of the Company held by Weigao Holding and Wego Capital for the purpose of Part XV of the SFO.

Save as disclosed above, as at 30 June 2026, no other persons (other than the Directors and chief executives of the Company) had any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO.

MAJOR CUSTOMERS AND SUPPLIERS

During the Period, the combined value of the Group's contracts with its five largest suppliers, which were not of a capital nature, was less than 30 per cent of the total value of supplies purchased. The Group's five largest customers combined contributed less than 30 per cent of its total revenue and other income during the Period.

During the Period, none of the Directors, their associates or any shareholders (which to the knowledge of the Director owned more than 5% of the Company's issued share capital) has a beneficial interest in the Group's five largest customers or suppliers.

CORPORATE GOVERNANCE

The Board is committed to high standards of corporate governance and recognises that good governance is vital for the long-term success and sustainability of the Group's businesses. The Company has adopted the code provisions as set out in the Corporate Governance Code (the "**Code**") contained in Appendix C1 to the Listing Rules. For the six months ended 30 June 2026, the Company has complied with all the code provisions as set out in the Code.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers ("**Model Code**") as set out in Appendix C3 of the Listing Rules as the standard for securities transactions by Directors. The Company had made specific enquiry of all Directors whether they have complied with the required standard set out in the Model Code during the six months ended 30 June 2026 and all Directors confirmed that they have complied with the Model Code during the six months ended 30 June 2026.

AUDIT COMMITTEE

The audit committee of the Company currently comprises four independent non-executive Directors, being Mr. Li Guohui (chairman of the audit committee), Mrs. Meng Hong, Mr. Li Qiang and Mr. Sun Heng; and one non-executive Director, being Mr. Tang Zhengpeng. The audit committee has reviewed the unaudited consolidated financial statement of the Company for the six months ended 30 June 2026 and considered that the relevant financial statements have been prepared in compliance with the applicable accounting principles and requirements of the Stock Exchange and other laws, and adequate disclosures have been made.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, the Company repurchased a total of 29,000,800 H shares of the Company ("**H Shares**") on the Stock Exchange. Details of the repurchases of shares are as follows:

		Price per H Share		
Month	**Number of H Shares repurchased**	**Highest**	**Lowest**	**Aggregate price (before expenses)**
		HK$	*HK$*	*HK$'000*
January	9,062,800	5.57	4.97	47,368
February	1,455,600	5.36	4.98	7,549
March	6,361,600	3.93	3.73	24,326
April	5,872,400	3.84	3.42	21,439
May	3,870,000	3.57	3.27	13,255
June	2,378,400	3.38	3.13	7,703
	29,000,800			121,640

Subsequently, the Company repurchased a total of 2,430,000 H Shares in July 2026 at the aggregate price of approximately HK$7,954,000 (before expenses).

All the repurchased H Shares are held as treasury shares.

Save as disclosed above, neither the Company, nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 June 2026.

ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES

At no time during the Period was the Company, its ultimate holding company or any subsidiaries of its ultimate holding company, a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

EVENTS AFTER THE REPORTING PERIOD

Pursuant to the conditional sale and purchase agreement dated 31 October 2025 and the supplemental agreement dated 5 January 2026 entered into among the Company, Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership) ("**Weihai Shengxi**"), Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership) ("**Weihai Ruiming**") and Shandong Weigao Blood Purification Products Co., Ltd. ("**Weigao Blood Purification**"), Weigao Blood Purification has agreed to acquire the entire equity interest in WEGO Prefills Pharmaceutical Packaging Co., Ltd. ("**WEGO Prefills**"), a non-wholly owned subsidiary of the Company, by issuing a total of 271,997,882 consideration shares in Weigao Blood Purification to the Company, Weihai Shengxi and Weihai Ruiming at an aggregate consideration of RMB8,510.81 million (the "**Weigao Blood Purification Transaction**").

Upon completion of the Weigao Blood Purification Transaction, WEGO Prefills will become a wholly-owned subsidiary of Weigao Blood Purification, and Weigao Blood Purification will become a non-wholly owned subsidiary of the Company. Further details of the Weigao Blood Purification Transaction are set out in the announcements of the Company dated 31 October 2025 and 5 January 2026.

The Weigao Blood Purification Transaction is conditional upon, among other things, the approval of the independent shareholders of each of the Company and Weigao Blood Purification and the approvals of the relevant regulatory authorities. The Weigao Blood Purification Transaction was approved by the independent shareholders of the Company at the extraordinary general meeting of the Company held on 12 February 2026 and by the independent shareholders of Weigao Blood Purification at the extraordinary general meeting of Weigao Blood Purification held on 27 February 2026. The Company was notified that the Weigao Blood Purification Transaction was approved by the Mergers and Acquisitions Restructuring Review Committee of the Shanghai Stock Exchange on 10 August 2026.

As at the date of this announcement, the Weigao Blood Purification Transaction has not been completed and remains subject to the registration and approval of the China Securities Regulatory Commission. The Company will make further announcement(s) as and when appropriate.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

25 August 2026
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing *(Executive Director)*
Mr. Cong Rinan *(Executive Director)*
Mr. Lu Junqiang *(Executive Director)*
Mr. Wang Daoming *(Executive Director)*
Mr. Chen Lin *(Non-executive Director)*
Mr. Tang Zhengpeng *(Non-executive Director)*
Mr. Li Guohui *(Independent Non-executive Director)*
Mrs. Meng Hong *(Independent Non-executive Director)*
Mr. Li Qiang *(Independent Non-executive Director)*
Mr. Sun Heng *(Independent Non-executive Director)*